Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price traded down 3.2% during mid-day trading on Friday . The stock traded as low as $4.14 and last traded at $4.23, with a volume of 97,666 shares changing hands. The stock had previously closed at $4.37.

Several equities analysts have recently issued reports on the company. Maxim Group set a $6.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday. FBR & Co set a $15.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday. Rodman & Renshaw reaffirmed a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a report on Friday, August 5th. Finally, Zacks Investment Research lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, June 1st.

The firm’s 50-day moving average is $2.97 and its 200 day moving average is $2.74. The stock’s market capitalization is $138.88 million.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. On average, equities research analysts predict that Abeona Therapeutics Inc. will post ($0.75) EPS for the current year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC boosted its stake in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.